VEGFR2 Pathway Studies show BPC-157 upregulates VEGFR2 mRNA and protein expression in vascular endothelial cells, promoting receptor internalization and activating downstream VEGFR2AkteNOS signaling (Hsieh et al., Journal of Molecular Medicine, 2017)
Through its angiogenic properties, BPC-157 promotes the growth of new blood vessels, significantly enhancing the healing of the myotendinous junction, which is typically a weak spot due to its poor vascularization [24, 38]
Even mild deficiency can show up as fatigue, bloating, or low motivation
Extends strength
Unknown Long-Term Effects : Human clinical data on BPC-157 covers fewer than 30 participants across 3 published pilot studies as of 2026
The total cost includes the price of the medication, plus a $25 monthly treatment plan fee that is added to the cost each month